Given that Thunderful’s shares will soon be delisted, the quarterly result is not important for shar...
Actic's positive trends, with strong cash flows and lower leverage, continued in Q4.
Redeye updates on Hacksaw after Q4-results which saw somewhat stronger-than-expected profitability w...
Redeye updates its estimates and valuation after Relais’ Q4 2025 report.
* Solid earnings momentum in Paving services * Divestment brings net cash position and dividend * M&...
Smart Eye delivered a strong Q4 within Automotive, significantly outperforming our expectations, whi...
Redeye comments on Camurus' Q4 report 2025, which was below our estimates due to a large sequential ...
Redeye provides an update following Corline’s Q4 2025 report.
* EEs down 16% to 2.6m, SEK 4.6m installations, EBIT 7% above us * Opex, market and installation tai...
* Weaker sales and maintained opex behind estimate cuts * We see relatively unchanged FCF '26e (SEK ...
* Annual revenue exceeds MSEK 200 * The bottom line disappoints in Q4 * We keep our fair value of SE...
Redeye provides an initial comment on Scandinavian ChemoTech’s Q4 2025 report.
Redeye provides an initial take following the release of Corline’s Q4 2025 report.
Aspo has EBITA improvement potential also this year as Telko and lower group costs contribute, but a...
Redeye views Catella's Q4 2025 results as broadly reassuring.
Redeye comments on SHH’s Q4 2025 report, which landed relatively in-line with the company’s prelimin...
Redeye shares its initial view on Modelon’s Q4 2025 report, which was softer than expected regarding...
Redeye provides its initial take on Moberg Pharma’s Q4 report, where sales greatly exceeded our expe...
Truecaller’s Q4 results align with its preliminary figures, highlighted by a significant margin beat...
* Q4 EBIT of SEK 11m, way below expectations driven by a SEK 151 impairment * Underlying Corporate F...
